We prospectively evaluated whether delivering a thermal dose of > 10 cumulative equivalent minutes at 43 degrees C to >90% of the @entity5 sites monitored (CEM43 degrees T90) would produce a pathologic complete response (pCR) in > 75% of high-grade soft @entity242 treated pre-operatively with thermoradiotherapy. The impact of thermal dose on local failure (LF), @entity3 ( @entity3 ), and @entity137 was also assessed. Thirty-five @entity1 > or = 18 years old with grade 2 or 3 soft @entity242 accessible for invasive thermometry were enrolled on the protocol. All @entity1 received megavoltage external beam radiotherapy (RT) in daily fractions of 1.8-2.0 Gy, five times a week, to a median total dose of 50 Gy and an initial @entity221 treatment (HT) of I h duration utilizing the BSD 2000 with Sigma 60 or @entity24477 applicators at frequencies of 60-140 MHz. Further HT was given for @entity1 with CEM43 degrees T90 > 0.5 after initial HT ('heatable' @entity1 ), twice a week to a maximum of 10 HT or CEM43 degrees T90 > 100. Of the 35 @entity1 entered, 30 had heatable @entity5 , one of which was inevaluable for pCR or LF as the @entity1 died of @entity3 prior to surgery, leaving 29 evaluable @entity1 . Of these 29 @entity1 , 15 (52%) had a pCR (95% CI: 37-73%), significantly less than the projected rate of > or = 75% (p = 0.02). Of the 25 heatable @entity5 that achieved CEM43 degrees T90 > or = 10, 14 (56%) had a pCR (95% CI: 39-78%) significantly less than the projected rate (p = 0.06). Three of the 29 @entity1 (10%) with heatable @entity5 had a LF, versus 1/5 unheatable @entity5 (p = 0.48). Fourteen of the 30 @entity1 (47%) with heatable @entity5 developed @entity3 , versus 2/5 unheatable @entity5 (p = 1.00). Ten of the 30 @entity1 (33%) with heatable @entity5 developed treatment-induced @entity137 . Thus, no correlation of thermal dose with histologic response was observed. Prospective control of CEM43 degrees T90 failed to achieve the projected pCR rate following pre-operative thermoradiotherapy for high-grade soft @entity242 , despite excellent local control. Possible explanations for this outcome are discussed.

A phase II trial testing the thermal dose parameter CEM43 degrees T90 as a predictor of response in soft XXXX treated with pre-operative thermoradiotherapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity242 :: ('MESH:D012509', 'Disease') :: ['tissue sarcomas'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour'] @entity24477 :: ('126364', 'Gene') :: ['MAPA'] @entity3 :: ('MESH:D009362', 'Disease') :: ['DM', 'distant metastasis'] @entity221 :: ('MESH:D005334', 'Disease') :: ['hyperthermia']
@entity242 :: (MESH:D012509,Disease) :: ['tissue sarcomas']
